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Diabetic nephropathy is the leading cause of chronic renal disease and a major cause of 
cardiovascular mortality in both developed and developing countries.  In type II diabetes 
patients with normoalbuminuria, fibrinogen production is increased, whereas that of albumin is 
normal. It is not known whether hepatic albumin production in albuminuric type II diabetes 
patients is also increased, and whether fibrinogen production is further increased in these 
patients. Knowledge of these potential relationships is important to understand both the 
mechanistic associations between albuminuria and hyperfibrinogenaemia. Therefore, this study 
was designed to measure fibrinogen and albumin concentrations in patients with type II 
diabetes who had normal or increased urinary albumin excretion. Subjects, materials, and 
methods: Plasma albumin, and fibrinogen concentrations and urinary albumin are measured in 
macroalbuminuric diabetic patients (n=16), microalbuminuric diabetic patients (n=16), and 
healthy controls (n=8).Results: A direct relationship was found between albuminuria and 
albumin concentration (r=0.59, p<0.05). Direct relationship also found between albuminuria 
and fibrinogen concentration (r=0.65, p<0.002), and fibrinogen pool (r=0.66, p<0.002). 
Conclusions: this study demonstrates that albumin and fibrinogen levels are increased in 
macroalbuminuric type II diabetes subjects compared with type II diabetes patients with 
microalbuminuria and healthy subjects , showing an upregulation of hepatic secretory proteins 
in this clinical condition. Such an upregulation seems to be responsible for the relative 
hyperfibrinogenaemia observed in the albuminuric diabetic patients.  
 
	  





Diabetic nephropathy is the leading cause of chronic 
renal disease and a major cause of cardiovascular 
mortality in both developed and developing countries 
(Bruno and Gross, 2000), (Valmadrid et al.,2000). 
Hyperfibrinogenaemia and albuminuria are established 
cardiovascular risk factors in diabetic and in non-
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diabetic populations (Ganda and Arkin, 1992), ( Fuller 
et al., 1979). Hyperfibrinogenaemia is common in type 
II diabetes, and is often associated with albuminuria 
(Jain et al., 2001), (Festa et al., 2002). Production of 
albumin and fibrinogen is increased in non-diabetic 
nephrotic syndromes (, suggesting coordinate changes 
in hepatic protein production in response to 
albuminuria (De Sain et al., 1998), (Zanetti et al., 
2001). In type II diabetes patients with 
normoalbuminuria, fibrinogen production is increased, 
whereas that of albumin is normal (Barazzoni et al., 
2000), (Tessari et al., 2006). It is not known whether 
hepatic albumin production in albuminuric type II 
diabetes patients is also increased, and whether 
fibrinogen production is further increased in these 
patients. Knowledge of these potential relationships is 








important to understand both the mechanistic 
associations between albuminuria and 
hyperfibrinogenaemia. Therefore, this study was 
designed to measure fibrinogen and albumin synthesis 
in patients with type II diabetes who had normal or 
increased urinary albumin excretion.                                                              
 
SUBJECTS, AND METHODS 
 
Subjects 
Thirty two male subjects with type II diabetes were 
included in this study (disease duration >3 years) from 
patients attending the Diabetes Centre at Suez General 
Hospital. Sixteen patients had a low urinary 
Albumin/cretinine ratio ACR (<300 mg/g; Alb−), 
whereas the remaining sixteen had an increased ACR 
(>300 mg/g; Alb+), based on two morning fresh void 
urine collections. The albuminuric patients were 
slightly older and had a slightly greater BMI, than the 
non-albuminuric patients, although the differences were 
not significant Table 1. Diabetes duration was, 
however, longer in the patients with albuminuria. All 
subjects had been adapted for 1 month to a standard 
weight-maintaining diet containing ≈50% of calories as 
carbohydrates, ≈20% as proteins and ≈30% as lipids in 
order to reduce the effect of diet on plasma proteins 
production. Daily protein intake was unrestricted and 
was at least > 1g/kg body weight in both patients’ 
groups. The hypoglycaemic therapy comprised diet 
only in two Alb− subject, diet plus oral hypoglycaemic 
agents (glyburide or gliclazide) in ten Alb− and in eight 
Alb+ subjects, oral hypoglycaemic agents plus insulin 
in 4 Alb−  and 2 Alb+ subjects, and split insulin doses 
in the remaining subjects. The patients’ metabolic 
control was poor, as shown by the elevated HbA1c 
concentration (Table 1), and it was not different in the 
two groups. Plasma creatinine concentration was 
normal in the Alb− patients, whereas it was moderately 
increased in the Alb+ patients (Table 1). Seven Alb− 
and all the Alb+ patients were on anti-hypertensive 
therapy, with combinations of angiotensin-converting-
enzyme inhibitors, diuretics, anti-adrenergic agents 
and/or calcium antagonists. All drugs were suspended 
the night before the study day. No patient had clinical 
signs of either oedema or pleural or abdominal liquid 
effusion. Background retinopathy and peripheral 
vascular insufficiency were found in three and four, 
respectively, of the Alb−, and in six and five, 
respectively, of the Alb+ patients. No Alb− subject had 
any clinical or biochemical evidence of ongoing 
inflammatory disease, as shown by normal leucocyte 
counts, erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP). In the Alb+ patients, the ESR 
was elevated in eleven subjects and CRP was mildly 
elevated in two subjects. No subject was a current 
smoker or had being smoking for at least 6 months 
prior to the study. Control studies were done in eight 
healthy male subjects Control subjects also recorded 
their food intake for 3 days and collected urine and 
fasting blood samples. Urine was analyzed for urea, 
creatinine, protein, albumin, and fibrinogen. All 
patients and volunteers agreed to participate after 
signing an informed consent form, in accordance with 
the Helsinki Declaration of Human Rights. The 





After ten hour fasting, Urine and intravenous blood 
samples are collected. Plasma insulin, glucagon, C-
peptide and fibrinogen concentration were measured 
according to (Jacques Wallach: Interpretation of 
Diagnostic Tests  2000). Plasma glucose, albumin, 
triglyceride, total and HDL cholesterol, and creatinine 
concentrations were determined by automatic methods 
using a COBAS Mira Auto Analyzer (Roche Italia, 
Milan, Italy) and specific reagents (Dade-Behring, 
Marburg, Germany). Plasma protein profiles were 
determined with standard electrophoresis. Circulating 
blood cells and the erythrocyte sedimentation rate were 
determined by photometrical capillary stopped-flow 
kinetic analysis (Test1TH; Alifax, Padova, Italy). C-
reactive protein was measured by nephelometry on a 
BN2 analyzer (Dade-Behring) (a non–high-sensitive 
assay). Glycated hemoglobin (HbA1C) was measured 




The "gold standard" to assess albuminuria is 24-hour 
urinary albumin excretion (UAE). Because 24-hour 
urine collection is cumbersome, American society of 
nephrology guidelines suggest measuring albuminuria 
in a first morning void, either as urinary albumin 
concentration (UAC) or adjusted for creatinine 
concentration, the albumin:creatinine ratio (ACR) ( 
Hiddo et al., 2008),( Holly et al., 2003). The albumin 
creatinine ratio is done to compare the amount of 
albumin that is passing into the urine from the kidneys 
compared to the amount of creatinine present. Although 
one can always check for albumin levels in the urine by 
doing a simple test, the advantage of calculating the 
albumin creatinine ratio is that this ratio remains 
unaffected by any kind of variation in the concentration 
in urine. The normal ratio of albumin to creatinine is 
seen to be around less than 30 mg/g of creatinine. In 
men, the level is seen to be less than or equal to 17 








mg/g of creatinine. When there is a high albumin 
creatinine ratio, that is, around 30 - 300 mg/g of 
creatinine, then it is known as microalbuminuria. This 
means that there is a small amount of albumin in the 
urine, which indicates that the kidneys may be slightly 
diseased. If the ratio of albumin to creatinine is more 
than 300 mg/g of creatinine, then the condition is 
known as macroalbuminuria, which means, there is a 
large amount of albumin in the urine.       
 
Table 1  
Clinical and biochemical characteristics of the type II 
diabetic patients with a lower (Alb−) or an increased (Alb+) 
urinary albumin excretion  
 Alb− type II 
diabetes 
(n=16) 
Alb+ type II 
diabetes 
(n=16) 
Age (years) 51±3 56±3 
BMI (kg/m2)  29.0±1.5 32.5±1.4 
Duration of disease (years) 9±2 16±3b  
HbA1c (%)  9.4±0.5 10.5±1.5 
Fasting glucose (mg/dl) 130±10 165±9a  
Insulin (nmol/l) 100±7 110±8 
Glucagon (pg/ml) 139±12 158±24 
C-peptide (ng/ml) 1.8±0.14 3.23±0.62a  
Erythrocyte sedimentation 
rate (mm) 
9.9±2.8 56.4±13.4b  
Urinary albumin excretion 
rate (mg/24 h) 
14.11±2.7 33.40±1.25b  
C-reactive protein (ng/ml) 3.32±0.02 4.56±0.55 
Creatinine (µmol/l) 76±3 145±25a  
Albumin (g/l) 41±1 44±2a  
Albumin pool (g) 142±4 130±8 
Fibrinogen (g/l) 3.65±0.27 4.86±0.41a  
Fibrinogen pool (g) 11.2±0.8 17.1±1.2b  
Total cholesterol (mmol/l) 5.37±0.28 5.38±0.28 
HDL cholesterol (mmol/l) 1.13±0.08 0.95±0.08 
Triglycerides (mmol/l) 1.55±0.25 1.32±0.17 





The patients with albuminuria had greater 
concentrations of plasma glucose, albumin, fibrinogen, 
C-peptide, creatinine and fibrinogen pool than the 
patients without albuminuria (Table 1).  
 The patients with albuminuria had greater 
concentrations of total plasma proteins, albumin, and 
fibrinogen compared to both patients with lower 
albuminuria and healthy control subjects (Table 2).  
 The patients with albuminuria had greater loss of 
albumin in urine, greater albumin concentration in 
urine and higher albumin/creatinine ratio compared to 
both lower albuminuric and healthy control subjects 
(Table 3). 
A direct relationship was found between albuminuria 
and albumin concentration (r=0.59, p<0.05). Direct 
relationship also found between albuminuria and 
fibrinogen concentration (r=0.65, p<0.002), and 
fibrinogen pool (r=0.66, p<0.002).  
 
Table 2 
Biochemical parameters in plasma from diabetic patients and 
control subjects 
 Alb− type 
II diabetes 
(n=16) 








71.11+1.4 74.31+0.5a,b 67.4+1.5 
Albumin  
g/L 
41±1 44±2a,b 36.2+0.5 
Fibrinogen 
g/L 
3.65±0.27 4.86±0.41a,b 3.0+0.2 
aStatistically significant difference vs the Alb− type 2 diabetic 
patients (p<0.05 or less), whereas bdenotes a statistically significant 




Biochemical parameters in urine from patients and control 
subjects 
 Alb− type II 
diabetes 
(n=16) 



















49±2.3 356.97±0.8a,b 8.2±1.25 
aStatistically significant difference vs the Alb− type 2 diabetic 
patients (p<0.05 or less), whereas bdenotes a statistically 
significant difference vs the healthy control subjects (p<0.05 or 





Albuminuria is a marker of renal damage and a 
hallmark of progression to renal insufficiency (Parving 
et al., 1992). It increases cardiovascular risk in type 2 
diabetes mellitus, probably because it reflects 
widespread increased vascular permeability causing 
organ damage (Parving et al., 1996), (Nannipieri et al., 
1995). Albuminuria and hyperfibrinogenaemia, another 
cardiovascular risk factor, are frequently associated  in 
diabetes (Jain et al., 2001), (Festa et al., 2002). Such an 
association is important in that fibrinogen, an acute-
phase protein, is a powerful and independent 
cardiovascular risk factor (Ganda and Arkin, 1992), 








(Fuller et al., 1979) . However, the mechanism(s) of the 
association between hyperfibrinogenaemia and 
albuminuria, as well as the response of hepatic albumin 
synthesis to albuminuria in type 2 diabetes, are not 
known.  
 In non-diabetic nephrotic syndromes albuminuria is 
associated with an upregulation of albumin synthesis, 
probably mediated by the decreased oncotic pressure at 
the hepatic level, which counteracts the increased 
urinary albumin loss. In these conditions, fibrinogen 
synthesis is also increased (De Sain et al., 1998), 
(Zanetti et al., 2001) suggesting an upregulation of 
hepatic secretory proteins. Thus, a link between 
albuminuria and the altered fibrinogen metabolism can 
be suspected also in type II diabetes, possibly at the site 
of liver production. However, whether these 
mechanisms are operating in type II diabetes as well is 
not known.  
 In this study we show that both albumin and 
fibrinogen productions are greater in type II diabetic 
patients with albuminuria than in patients with a lower 
urinary excretion rate. Positive correlations between the 
degree of albuminuria and both albumin and fibrinogen 
plasma levels have been found. These observations 
suggest that upregulation of hepatic protein synthesis, 
probably in response to the increased urinary albumin 
loss, operates in type II diabetes with nephropathy. 
Albuminuria was also directly correlated with 
fibrinogen concentrations and the circulating pool of 
fibrinogen. These data indicate that albuminuria in type 
II diabetes may represent a trigger for increased 
albumin production, as well as for a further increase of 
fibrinogen concentrations and production. This may be 
mediated by decreased oncotic pressure caused by 
albuminuria. 
 That fibrinogen synthesis is increased in type II 
diabetes, even in the absence of micro- or 
macroalbuminuria, has been previously demonstrated 
(Barazzoni et al., 2001), (Barazzoni et al., 2003). The 
present study showed that a further increase   in 
fibrinogen concentration occurs when type II diabetes 
patients are also albuminuric (Table 1). On the whole, 
the additional cardiovascular risk associated to 
albuminuria may be, at least partly, the result of the 
increased fibrinogen concentration of these patients.  
 The mechanism(s) possibly associated with the 
increased fibrinogen production in type II diabetes have 
been previously discussed (Barazzoni et al., 2001), 
(Tessari et al., 2006) and may include insulin 
resistance, hyperglucagonaemia, increased fibrinogen 
degradation products acting as stimulators of fibrinogen 
production in the liver, and possibly, also a subclinical 
inflammatory state otherwise not detectable by standard 
assays. In our albuminuric type II diabetes patients, the 
increased ESR, which is a common finding in 
albuminuria (Liverman et al., 1988), may indicate the 
occurrence of a mild inflammatory state, despite the 
normality of other biochemical (leucocytic count, urine 
analysis) and clinical indices of inflammation, with the 
exception of a mild increase of CRP. Therefore, in 
addition to the previously mentioned factors, a 
subclinical inflammatory condition, with the associated 
expected changes in inflammatory cytokines (that were 
not measured in this study), may represent a stimulus 
towards increased fibrinogen production. On the other 
hand, that inflammation cannot be the only cause of the 
observed metabolic increase in hepatic protein 
synthesis is supported by the fact that albumin is a 
negative acute-phase protein (Gordon, 1976), therefore 
its synthesis should be depressed, and not increased, by 
inflammation, which is in contrast with our present 
findings. Since diabetes duration was greater in the 
albuminuric patients than in the non-albuminuric 
patients, disease duration could represent an additional 
variable in the observed findings. 
 Albumin synthesis is physiologically stimulated by 
insulin and amino acids (Doweiko and Nompleggi, 
1991), (De Feo et al., 1991). Although insulin 
concentration was similar in both groups, the increased 
C-peptide concentration, an index of increased 
endogenous insulin secretion, observed in the 
albuminuric subjects could constitute a factor 
contributing to their increased albumin synthesis.  
Age difference between the two groups may have a 
confounding role on albuminuria-associated increased 
albumin and fibrinogen production in type II diabetes.  
The albuminuric diabetic patients had a moderate 
increase of creatinine concentration (Table 1). Impaired 
kidney function in these patients may theoretically 
affect plasma protein production in the albuminuric 
type II diabetes group.  
 The fact that all the albuminuric patients were 
receiving hypotensive drugs, as opposed to a lower 
number of subjects being treated in the 
normoalbuminuric group, might have affected the 
results because fibrinogen concentration can be reduced 
by angiotensin-converting-enzyme inhibitor (Fogari et 
al., 1998). However, because the fibrinogen 
concentration was greater in the albuminuric patients 
despite their drug therapy, their fibrinogen levels might 
have been even greater than those observed here.   
 In conclusion, this study demonstrates that albumin 
and fibrinogen levels are increased in 
macroalbuminuric type II diabetes subjects compared 
with type II diabetes patients with microalbuminuria 
and healthy subjects , showing an upregulation of 
hepatic secretory proteins in this clinical condition. 
Such an upregulation seems to be responsible for the 








relative hyperfibrinogenaemia observed in the 
albuminuric diabetic patients. Albuminuria, through as 
yet unknown mechanisms, could thus represent a key 
factor. This study casts new light on the 
pathophysiological mechanisms of the association 
between albuminuria and hyperfibrinogenaemia in type 
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